Article Text

Download PDFPDF
Mutational analysis of N-ras, p53, CDKN2A (p16INK4a), p14ARF, CDK4, and MC1R genes in human dysplastic melanocytic naevi
  1. T Papp1,
  2. H Pemsel1,
  3. I Rollwitz1,
  4. H Schipper1,
  5. D G Weiss1,
  6. D Schiffmann1,
  7. R Zimmermann2
  1. 1Institute for Cell Biology and Biosystem Technology, University of Rostock, Rostock, Germany
  2. 2Institute for Dermatology, University of Rostock, Rostock, Germany
  1. Correspondence to:
 Dr T Papp, University of Rostock, Department of Biological Sciences, Institute for Cell Biology and Biosystem Technology, Albert-Einstein-Strasse 3, 18051 Rostock, Germany;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In order to detect possible dysplastic melanocytic naevi (DMN) associated melanoma risk factors and lesion specific differences in the mutation spectrum of dysplastic and congenital melanocytic naevi (CMN), we screened 19 specimens of human sporadic DMN derived from 19 patients for the presence of mutations in five genes, which we had investigated in a former study in 19 CMN1 and which have been reported to be associated with human cutaneous melanoma (N-ras,2p53,3CDKN2A,4CDK4,5 and MC1R6,7).


DNA was extracted from selected paraffin embedded DMN resection specimens using the QIAamp DNA Mini Kit (Qiagen) according to the recommendations of the supplier. The relative number of atypical melanocytes in the DMN and the histological subtype of the DMN were determined in parallel slides by an experienced dermatologist (Dr Regina Zimmermann) (table 1).

View this table:
Table 1

N-ras mutations and MC1R variants in human spontaneous dysplastic naevi

The screening strategy for the detection of activating point mutations in the oncogenes N-ras and CDK4 as well as for germline sequence variants in the MC1R gene by combined RFLP-PCR/SSCP analysis, and the screening strategy for the detection of homozygous deletions and point mutations in the tumour suppressor genes p53 and CDKN2A by combined multiplex-PCR/SSCP analysis, have been described previously.1 In order to …

View Full Text